NFKB1 and melanoma: Although local inflammation and activated NF-κB signaling have been associated with TMZ treatment and resistance in both GBM and melanoma [13,34,35], the involvement of NLRP or NLRP inflammasomes has not been nowadays reported in the development of drug resistance in any cells.